Details for Patent: 7,144,884
✉ Email this page to a colleague
Which drugs does patent 7,144,884 protect, and when does it expire?
Patent 7,144,884 protects TRINTELLIX and is included in one NDA.
Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-nine patent family members in thirty-six countries.
Summary for Patent: 7,144,884
Title: | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Abstract: | The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder ##STR00001## |
Inventor(s): | Ruhland; Thomas (Roskilde, DK), Smith; Garrick Paul (Valby, DK), Bang-Andersen; Benny (Copenhagen, DK), Puschl; Ask (Frederiksberg, DK), Moltzen; Ejner Knud (Gentofte, DK), Andersen; Kim (Ridgewood, NJ) |
Assignee: | H. Lundbeck A/S (Copenhagen-Valby, DK) |
Application Number: | 10/488,280 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,144,884 |
Patent Claim Types: see list of patent claims | Compound; Composition; Use; | More… ↓ |
Drugs Protected by US Patent 7,144,884
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,144,884
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Denmark | 2001 01466 | Oct 04, 2001 |
PCT Information | |||
PCT Filed | October 02, 2002 | PCT Application Number: | PCT/DK02/00659 |
PCT Publication Date: | April 10, 2003 | PCT Publication Number: | WO03/029232 |
International Family Members for US Patent 7,144,884
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1436271 | ⤷ Subscribe | 300652 | Netherlands | ⤷ Subscribe |
European Patent Office | 1436271 | ⤷ Subscribe | C300652 | Netherlands | ⤷ Subscribe |
European Patent Office | 1436271 | ⤷ Subscribe | PA2014013 | Lithuania | ⤷ Subscribe |
European Patent Office | 1436271 | ⤷ Subscribe | 92397 | Luxembourg | ⤷ Subscribe |
European Patent Office | 1436271 | ⤷ Subscribe | CR 2014 00030 | Denmark | ⤷ Subscribe |
European Patent Office | 1436271 | ⤷ Subscribe | 14C0033 | France | ⤷ Subscribe |
European Patent Office | 1436271 | ⤷ Subscribe | C20140012 00108 | Estonia | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |